

# STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

#### PILOCARPINE SOLUTION

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
PILOCARPINE HCL	VUITY		51425		

#### **GUIDELINES FOR USE**

## **INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

- 1. Does the patient have a diagnosis of presbyopia and meet ALL of the following criteria?
  - The patient is 18 years of age or older
  - Therapy is prescribed by or in consultation with an ophthalmologist or optometrist
  - The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient's vision
  - The patient had a trial of or contraindication to generic pilocarpine ophthalmic solution

If yes, approve for 3 months by GPID with a quantity limit of #5mL per 30 days. If no, do not approve.

INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PILOCARPINE SOLUTION (Vuity)** requires the following rule(s) be met for approval:

- A. You have presbyopia (not able to focus on nearby objects)
- B. You are 18 years of age or older
- C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
- D. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- E. You had a trial of or contraindication (harmful for) to generic pilocarpine ophthalmic (eye) solution

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

#### **CONTINUED ON NEXT PAGE**

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Created: 11/12/2021 Page 1 of 2



## STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

#### PILOCARPINE SOLUTION

### **GUIDELINES FOR USE (CONTINUED)**

### **RENEWAL CRITERIA**

- 1. Does the patient have a diagnosis of presbyopia and meet **ALL** of the following criteria?
  - The patient is not using corrective lenses OR corrective lenses are insufficient to completely correct patient's vision
  - The patient continues to have benefit from Vuity

If yes, approve for 12 months by GPID with a quantity limit of #5mL per 30 days. If no, do not approve.

RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **PILOCARPINE SOLUTION (Vuity)** requires the following rule(s) be met for renewal:

- A. You have presbyopia (not able to focus on nearby objects)
- B. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
- C. You continue to have benefit from Vuity

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

#### **RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Vuity.

#### **REFERENCES**

• Vuity [Prescribing Information]. North Chicago, IL: AbbVie, Inc.; October 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 11/21

Commercial Effective: 11/19/21 Client Approval: P&T Approval: 10/21

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Created: 11/12/2021 Page 2 of 2